BCNU (Carmustine) and Gliadel (Carmustine Wafers)

From Glioblastoma Treatments
Revision as of 06:10, 24 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=BCNU and Gliadel Wafers |FDA_approval=Yes |used_for=High-grade gliomas |clinical_trial_phase=Phase III (Europe for Gliadel) |common_side_effects=Low blood counts, pulmonary problems, infection, and seizures for Gliadel |OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months |usefulness_rating=4 |notes=While Gliadel wafers alone offer modest improvement, combining them with the standard...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name BCNU and Gliadel Wafers
Overview
FDA Approval Yes
Used for High-grade gliomas
Clinical Trial Phase Phase III (Europe for Gliadel)
Clinical Trial Explanation Not specified
Common Side Effects Low blood counts, pulmonary problems, infection, and seizures for Gliadel
OS without Not specified
OS with Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months
PFS without Not specified
PFS with Not specified
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.


From Ben Williams Book: Not specified

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=BCNU_(Carmustine)_and_Gliadel_(Carmustine_Wafers)&oldid=107"